Molecular biologic assessment of cutaneous specimens of ocular rosacea

Ophthalmic Plastic and Reconstructive Surgery

Volumn 28, Issue 4, 2012, Pages 246-250

  Wladis, Edward J ^a   Iglesias, Bibiana V ^a   Adam, Alejandro P ^a   Gosselin, Edmund J ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 16; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOKINE; STEM CELL FACTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; EYE DISEASE; FEMALE; HUMAN; HUMAN TISSUE; MALE; OCULAR ROSACEA; PRIORITY JOURNAL; SKIN BIOPSY; SKIN INFLAMMATION;

BIOPSY; CHEMOKINE CCL2; CHEMOKINE CXCL9; FEMALE; HUMANS; INTERLEUKIN-16; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; ROSACEA; SKIN; STEM CELL FACTOR;

EID: 84863982314     PISSN: 07409303     EISSN: 15372677     Source Type: Journal    
DOI: 10.1097/IOP.0b013e31824dd9d4     Document Type: Article

References (32)

1. Afonso AA, Sobrin L, Monroy DC, et al. Tear fluid gelatinase B activity correlates with IL-1alpha concentration and fluorescein clearance in ocular rosacea. Invest Ophthalmol Vis Sci 1999;40:2506-12.
2. Jenkins MS, Brown SI, Lempert SL, et al. Ocular rosacea. Am J Ophthalmol 1979;88(3 Pt 2):618-22.
3. Akpek EK, Merchant A, Pinar V, et al. Ocular rosacea: Patient characteristics and follow-up. Ophthalmology 1997;104:1863-7.
4. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42.
5. Oltz, Check J. Rosacea and its ocular manifestations. Optometry 2011;82:92-103.
6. Key JE: A comparative study of eyelid cleaning regimens in chronic blepharitis. CLAO J 1996;22:209-12.
7. Greiner JV, Leahy CD, Glonek T, et al. Effects of eyelid scrubbing on the lid margin. CLAO J 1999;25:109-13.
8. Barton K, Monroy DC, Nava A, et al. Inflammatory cytokines in the tears of patients with ocular rosacea. Ophthalmology 1997;104:1868-74.
9. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;17(14):3720-32.
10. Stahl N, Radin A, Mellis S. Rilonacept-CAPS and beyond. Ann NY Acad Sci 2009;1182:124-34.
11. Church LD, McDermott MF. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009;11:81-9.
12. Owyang AM, Issafras H, Corbin J, et al. XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases. MAbs 2011;3:49-60.
13. Matoba T, Egashira K. Anti-inflammatory gene therapy for cardiovascular disease. Curr Gene Ther 2011;11:442-6.
14. Skundric DS, Dai R, Zakarian VL, et al. Anti-IL-16 therapy reduces CD4+ T-cell infiltration and improves paralysis and histopathology of relapsing EAE. J Neurosci Res 2005;79:680-93.
15. Yamasaki K, Di Nardo A, Bardan A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med 2007;13:975-80.
16. Elssner A, Duncan M, Gavrillin M, et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1? release and processing. J Immunol 2004;172:4987-94.
17. Yu J, Mookherjee N, Wee K, et al. Host defense peptide LL-37, in synergy with inflammatory mediator IL-1beta, augments immune responses by multiple pathways. J Immunol 2007;179:7684-91.
18. Egesten A, Eliasson M, Johansson HM, et al. The CXC chemokine MIG/CXCL9 is important in innate immunity against Streptococcus pyogenes. J Infect Dis 2007;195:684-93.
19. Gu Y, Lewis DF, Deere K, et al. Elevated maternal IL-16 levels, enhanced IL-16 expressions in endothelium and leukocytes, and increased IL-16 production by placental trophoblasts in women with preeclampsia. J Immunol 2008;181:4418-22.
20. Shimada Y, Takehara K, Sato S. Both Th2 and Th1 chemokines (TARC/CCL17, MDC/CCL22, and Mig/CXCL9) are elevated in sera from patients with atopic dermatitis. J Dermatol Sci 2004;34:201-8.
21. Frezzolini A, Paradisi M, Zaffiro A, et al. Circulating interleukin 16 (IL-16) in children with atopic/eczema dermatitis syndrome (AEDS): A novel serological marker of disease activity. Allergy 2002;57:815-20.
22. Masuda K, Katoh N, Soga F, et al. The role of interleukin-16 in murine contact hypersensitivity. Clin Exp Immunol 2005;140:213-19.
23. Liu W, Ding I, Chen K, et al. Interleukin 1beta (IL1B) signaling is a critical component of radiation-induced skin fibrosis. Radiat Res 2006;165:181-91.
24. Cooper KD, Hammerberg C, Baadsgaard O, et al. Interleukin-1 in human skin: Dysregulation in psoriasis. J Invest Dermatol 1990;95(5 Suppl):24-6S.
25. Nakamura K, Williams IR, Kupper TS. Keratinocyte-derived monocyte chemoattractant protein 1 (MCP-1): Analysis in a transgenic model demonstrates MCP-1 can recruit dendritic and Langerhans cells to skin. J Invest Dermatol 1995;105:635-43.
26. Yamamoto T, Katayama I, Nishioka K. Expression of stem cell factor in the lesional skin of systemic sclerosis. Dermatology (Basel) 1998;197:109-14.
27. Smith JR, Lanier VB, Braziel RM, et al. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 2007;91:226-9.
28. Wang JG, Williams JC, Davis BK, et al. Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. Blood 2011;118:2366-74.
29. Brecht A, Bartsch C, Baumann G, et al. Relaxin inhibits early steps in vascular inflammation. Regul Pept 2011;166:76-82.
30. Dentelli P, Rosso A, Balsamo A, et al. C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium. Blood 2007;109:4264-71.
31. Abu El-Asrar AM, Struyf S, Opdenakker G, et al. Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes. Mol Vis 2010;16:1098-107.
32. Wakabayashi Y, Usui Y, Okunuki Y, et al. Increased levels of monokine induced by interferon-gamma (Mig) in the vitreous of patients with diabetic retinopathy. Diabet Med 2008;25:875-7.